SRP-9001 (delandistrogene moxeparvovec)
Duchenne Muscular Dystrophy (DMD)
ApprovedCommercial
Key Facts
About Sarepta Therapeutics
Sarepta Therapeutics is a pioneering, commercial-stage biotech focused on developing and commercializing precision genetic medicines for devastating rare diseases, primarily Duchenne muscular dystrophy. The company has multiple FDA-approved exon-skipping therapies on the market and is advancing a robust pipeline that includes a commercial gene therapy and other candidates for DMD and limb-girdle muscular dystrophy (LGMD). With a hybrid manufacturing strategy and a relentless focus on following the science, Sarepta aims to reclaim futures for patients impacted by rare genetic disorders.
View full company profileTherapeutic Areas
Other Duchenne Muscular Dystrophy (DMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AOC Program | Avidity Biosciences | Clinical |
| AGAMREE® (vamorolone) | Catalyst Pharmaceuticals | Approved/Commercial |
| Deramiocel (CAP-1002) | Capricor Therapeutics | Phase 3 |
| RGX-202 | REGENXBIO | Phase 1/2 |
| PBGENE-DMD | Precision BioSciences | Phase 1/2 |
| DT-DEC01 | Dystrogen Therapeutics | Phase 1 |